4D Molecular Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by 4D Molecular Therapeutics, Inc. (FDMT) on May 23, 2022. The report details the results of the Company's 2022 Annual Meeting of Stockholders, which was held virtually on the same date. The record date for the meeting was March 28, 2022, with 32,251,924 shares of common stock outstanding.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and does not contain financial performance data.
Material Changes and Voting Results
Two proposals were submitted to a vote of security holders. A total of 27,300,458 shares were voted in person or by proxy.
- Proposal 1: Election of Class II Directors
- Jacob Chacko, M.D., MBA: Elected with 22,743,786 votes for, 2,475,579 withheld, and 2,081,093 broker non-votes.
- Susannah Gray, MBA: Elected with 22,885,958 votes for, 2,333,407 withheld, and 2,081,093 broker non-votes.
- Charles P. Theuer, M.D., Ph.D.: Elected with 16,744,107 votes for, 8,475,258 withheld, and 2,081,093 broker non-votes.
- Proposal 2: Ratification of Independent Auditor
- Stockholders ratified the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
- Votes: 27,290,906 For, 3,217 Against, 6,335 Abstain.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the reporting of voting outcomes.
Key Facts for Investor Verification
- Verify the tenure of the newly elected Class II directors, who will serve until the 2025 Annual Meeting.
- Note the significant number of votes withheld for director nominee Charles P. Theuer (8,475,258) compared to the other nominees.
- Confirm the appointment of PricewaterhouseCoopers LLP as the auditor for the 2022 fiscal year.
- Review the Definitive Proxy Statement on Schedule 14A filed on April 13, 2022, for detailed background on the proposals.